PTCISB/08x (08-03)
Approved for use through 07/31/2006 (08) 0851-0301
U.S. Petient and Trademark Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to resp

	Application Number			
INFORMATION DIGGS COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Cor		melis L. G. HAM	
	Art Unit			
	Examiner Name			
	Attorney Docket Number	ır	PHNL031281US	

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No			Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5406204		1995-04-11	Monich, et al.	all		
	2	5736858		1998-04-07	Katzneison, et al.	all		
	3	6078177		2000-06-20	Petropoulos, et al.	all		
	4	6311389	B1	2001-11-06	Uosaki, et al.	all		
	5	6479999	B1	2002-11-12	DeMeester, et al.	all		
If you wisl	h to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			Columns,Lines where nt Passages or Relevant s Appear		
	1	20020175684	A1	2002-11-28	Schaaf .	all		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		
iling Date		
rst Named Inventor Corr		nelis L. G. HAM
rt Unit		
xaminer Name		
Marriero Darabat Morack		DUNI 034304UC

Date Considered

	2	20040189298	A1	2004-0	9-30	Vavrek, et al.		all		
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto	n. Add	
	FOREIGN PATENT DOCUMENTS Remove									
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Line where Relevant Passages or Relevan Figures Appear	T5
	1	2 364 784	GB		А	2002-02-06	Siemens		all	
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		
	1 XIMM_INGEN, R., et al.; Gradent System Providing Continuously Variable Field Characteristics; 2002; Magnetic Resonance in Medicine; 47:800-808.									
If you wish to add additional non-patent literature document citation information please click the Add button Add										

A

E

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTD Patent Documents at sever-USPTD,GDV or MPEP 991.64. I Enter office that issued the document, by the two-letter code (WiPDE Standard ST.3.) For Japanese patent documents, the indication of the year of the regin of the Improve must precede the serial number of the patent documents of the patent document with the Patent Standard ST.16 (9) as possible. I Applicate in 5 paics a choice of more characteristics and the Patent Standard ST.16 (9) as possible. I Applicate in 5 paics a choice of more than the Patent Standard ST.16 (9) as possible. I Applicate in 5 paics a choice of more than the Patent Standard ST.16 (9) as possible. I Applicate in 5 paics a choice of more than the Patent Standard ST.16 (9) as part of the Patent Standard ST.16 (9) as part of the Patent ST.16 (9) and the Patent ST.16 (9) as part of the Patent ST.16 (9) as patent ST.16 (9) as part of the Patent ST.16 (9) as pate

EXAMINER SIGNATURE

Examiner Signature

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the a	appropriate	selection(s):
---------------	----------	-------------	------------	-------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.39(file).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.	an or the signature.								
Signature	/TML/	Date (YYYY-MM-DD)	2006-04-26						
Name/Print	Thomas M. Lundin	Registration Number	48979						

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.